See every side of every news story
Get Started
SubscribeLogin
SAG Awards
Olaf Scholz
Israel-Hamas Conflict
Military
Ukraine War
Hamas
Wrestling
Donald Trump
Elon Musk
Basketball
US Politics
Pope Francis
Published • loading... • Updated

Amplitude Vascular Systems Secures $36M to Advance Treatment for Calcified Arterial Disease

Summary by hitconsultant.net
What You Should Know: –  Amplitude Vascular Systems (AVS), a medical device company focused on safely and effectively treating severely calcified arterial disease with its novel PULSE IVL™ platform, announced today that it has completed a Series B round of financing of $36M.  –  The funding will support the U.S. peripheral commercial launch as well as U.S. coronary and carotid IDE trials for the company’s Pulse Intravascular Lithotripsy™ (PIVL™)…
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

7 Articles

All
Left
Center
Right
cardiovascularbusiness.comcardiovascularbusiness.com

Medical device company raises $36M for emitter-free IVL platform

Boston-based Amplitude Vascular Systems is busy investigating the performance of its Pulse IVL platform in a wide variety of patient populations.

Read Full Article
Medical Device NetworkMedical Device Network

AVS secures $36m to support US launch of Pulse IVL device

AVS has announced the completion of a $36m Series B financing round to support the peripheral commercial launch of its Pulse IVL.The post AVS secures $36m to support US launch of Pulse IVL device appeared first on Medical Device Network.

Read Full Article
hitconsultant.nethitconsultant.net

Amplitude Vascular Systems Secures $36M to Advance Treatment for Calcified Arterial Disease

What You Should Know: –  Amplitude Vascular Systems (AVS), a medical device company focused on safely and effectively treating severely calcified arterial disease with its novel PULSE IVL™ platform, announced today that it has completed a Series B round of financing of $36M.  –  The funding will support the U.S. peripheral commercial launch as well as U.S. coronary and carotid IDE trials for the company’s Pulse Intravascular Lithotripsy™ (PIVL™)…

Read Full Article
Interventional NewsInterventional News

AVS completes US$36 million Series B financing ahead of IVL US commercial launch - Interventional News

AVS console Amplitude Vascular Systems (AVS) recently announced that it has completed a Series B round of financing of US$36 million. The funding will support the US peripheral commercial launch as well as US coronary and carotid investigational device exemption (IDE) trials for the company’s Pulse intravascular lithotripsy (PIVL) device. “We are pleased to see strong, sustained investor excitement around this technology,” said Mark Toland, chai…

Read Full Article
Cardiovascular NewsCardiovascular News

AVS completes US$36 million Series B financing ahead of IVL US commercial launch - Cardiovascular News

Amplitude Vascular Systems (AVS) recently announced that it has completed a Series B round of financing of US$36 million. The funding will support the US peripheral commercial launch as well as US coronary and carotid investigational device exemption (IDE) trials for the company’s Pulse intravascular lithotripsy (PIVL) device. “We are pleased to see strong, sustained investor excitement around this technology,” said Mark Toland, chairman of the …

Read Full Article
Medical Alley AssociationMedical Alley Association

AVS Completes a $36M Series B Financing Ahead of IVL U.S. Commercial Launch - Medical Alley

January 28, 2025 08:00 AM Eastern Standard Time BOSTON–(BUSINESS WIRE)–Amplitude Vascular Systems (AVS), a medical device company focused on safely and effectively treating severely calcified arterial disease with its novel PULSE IVL platform, announced today that it has completed a Series B round of financing of $36M. The funding will support the U.S. peripheral commercial launch as well as U.S. coronary and carotid IDE trials for the company’s…

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Endovascular Today broke the news in on Tuesday, January 28, 2025.
Sources are mostly out of (0)

Similar News Topics

Boston, Massachusetts

Boston, Massachusetts

News
For You
Search
BlindspotLocal